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Abstract
The present study was aimed at exploring the prevalence and factor structure of methamphetamine (MA)
psychotic symptoms. The data were obtained from a cross-country evaluation of substance use, health,
and treatment in MA psychotic in-patients. The prevalence rates of lifetime and current psychotic symp-
toms were determined by using Mini-International Neurospychiatric Interview-Plus, Module M. The
Manchester scale was used to assess the severity of psychotic symptoms during the week prior to
assessment. All eight items of the Manchester scale were subjected to principal-component analysis,
eigenvalue one test, and varimax rotation. The data of 168 patients (127 male and 41 female) included
in the analyses were obtained from Australia, Japan, the Philippines and Thailand. Persecutory delusion
was the most common lifetime psychotic symptom found in 130 participants (77.4%), followed by
auditory hallucinations, strange or unusual beliefs, and thought reading. Auditory hallucinations were
the most common current symptom found in 75 participants (44.6%), followed by strange or unusual
beliefs and visual hallucinations. Current negative symptoms were also found in 36 patients (21.4%).
Apart from a factor of anxiety and depression, the results yielded a two-factor model of MA psychotic
symptoms, which were negative and positive/disorganized syndromes. The negative syndrome com-
prised poverty of speech, psychomotor retardation, and ﬂattened/incongruous aﬀects. The positive
syndrome consisted of delusions, hallucinations, and incoherent speech. Both positive/disorganized and
negative syndromes should be taken into account in assessing MA psychotic symptoms. The clinical
ﬁndings do not support the shortcomings of amphetamine-induced psychosis in modelling the negative
symptoms of schizophrenia.
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Introduction
Methamphetamine (MA) psychosis or MA-induced
psychotic disorder is perhaps one of the most widely
known phenomena associated with chronic, high-
dose, and/or continuous use of MA (Bell, 1973 ;
Griﬃth et al., 1972 ; Hall et al., 1996). It is commonly
described as closely simulating paranoid schizo-
phrenia (Bell, 1965 ; Snyder, 1973). Moreover, both
psychotic disorders usually respond to antipsychotic
medications, which have dopaminergic antagonist
properties (Angrist et al., 1974). The resemblance in
many aspects between an amphetamine psychosis and
schizophrenia has made this compound a primary
psychotomimetic model agent in schizophrenia re-
search.
As MA is widely used, MA psychosis is a common
psychiatric problem in many parts of the world. The
results of a recent survey have shown that the number
of amphetamine-type stimulant users, in particular
MA users, has surpassed those of opiate and cocaine
users combined (United Nations Oﬃce for Drug
Control and Crime Prevention, 2000). This leads to
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markedly increased proportions of MA psychotic
patients in many mental health settings.
Although clinical evidence is needed to serve MA
psychotic patients, few studies have been carried out
in this area. In many respects, symptoms studies
may be a priority because the results can be used as
basic knowledge for further studies of MA psychosis,
e.g. aetiology, course, prognosis, and treatment. In
addition, the results of such studies could be used to
ascertain the shortcomings of amphetamine-induced
psychosis in modelling the negative (psychotic) or
deﬁcit symptoms of schizophrenia that have been
discussed over the past decades (Javitt and Zukin,
1991 ; Sams-Dodd, 1995).
In MA psychosis, negative symptoms are much less
commonly reported compared to positive (psychotic)
symptoms. While most studies found high prevalence
of delusions and hallucinations (Ellinwood, 1967;
Kalant, 1966 ; Sato, 1992), very few of them mentioned
negative symptoms, e.g. poverty of speech, psycho-
motor retardation, and a ﬂattened aﬀect. Although
these studies closely examined the patients, one limi-
tation of them appears to be the unsystematic evalu-
ation of psychotic symptoms. Further, most studies
were carried out before the concept of negative
symptoms was widely accepted.
Previous ﬁndings of MA psychotic symptoms
appear to be dissimilar to those of functional psychotic
symptoms. While negative symptoms are rarely
reported in MA psychosis, both positive and nega-
tive symptoms are found in functional psychoses
(McIntosh et al., 2001 ; Ratakonda et al., 1998). Whether
the prevalence of MA negative symptoms is actually
low needs investigation. As the existence of negative
syndrome in MA psychosis is not yet known, this
evidence has implications not only for clinical practice
but also for research, such as choosing appropriate
outcomes and measures for MA psychotic patients. In
addition, if negative symptoms are not an important
part of MA psychosis, MA psychotic symptoms may
be diﬀerent from schizophrenic psychotic symptoms,
and amphetamine-induced psychosis should not be
used as a model of schizophrenia.
Other than the prevalence of psychiatric symptoms,
factor analysis is another approach of symptoms study.
This statistical technique can be used to determine
which symptoms items are combined to generate
a given factor or syndrome, as well as the clinical
heterogeneity of mental disorders. The past decades
have witnessed the beneﬁts of using factor analytic
studies in many psychiatric disorders, in particular,
schizophrenia. Up to eight factor dimensions have
been found to explain the psychopathology of
schizophrenia (Peralta and Cuesta, 2001). The use of
multifactor models has led to the ﬁndings of two or
more underlying pathological processes and treatment
response patterns in schizophrenic patients (Buchanan
and Carpenter, 1994). In other functional psychotic
and mood disorders, a three- or four-factor model has
been found (McIntosh et al., 2001 ; Ratakonda et al.,
1998). Although these studies were carried out in
patients with functional psychoses, a negative syn-
drome was commonly found. To our knowledge, no
factor analytical study of MA psychotic symptoms has
previously been undertaken. We, therefore, propose to
explore the factor structure, as well as the prevalence,
of MA psychotic symptoms.
Methods
The data included in this study were obtained
from a strand of the World Health Organization
Amphetamine-Type Stimulant (ATS) Project related to
a cross-country evaluation of MA psychosis. This
strand was concurrently carried out in in-patient
psychiatric units of several hospitals in Australia,
Japan, the Philippines and Thailand. The study
protocol was approved by the Ethics Committee of
each participating hospital or institution. Written in-
formed consent was obtained from each participant
after the procedure had been fully explained.
The inclusion criteria for a participant were : (i)
methamphetamine use during the week prior to the
admission; (ii) evidence of substance-induced psy-
chotic disorder ; and (iii) the ability to understand the
purpose of the study and complete study interviewing
materials. The exclusion criteria were : (i) prior history
of psychotic disorders not caused by substance use;
(ii) risk of violence to clinical staﬀ; (iii) severe risk of
self-harm; and (iv) impaired sensorium. All patients
were interviewed by trained psychiatrists within 3–7 d
of admission.
Data relevant to substance use, health, and treat-
ment were collected, but only those related to psy-
chotic symptoms are presented here. The presence of
lifetime and current psychotic symptoms was assessed
by using the Mini-International Neuropsychiatric
Interview-Plus (MINI-Plus), Module M. The MINI-
Plus is a more detailed version of the MINI, a struc-
tured clinical interview for psychiatric diagnosis
(Sheehan et al., 1998). Its reliability and validity have
been tested and are comparable to the Structured
Clinical Interview for Diagnostic and Statistical
Manual (DSM)-III-R patient version diagnoses
(SCID-P) and the Composite International Diagnostic
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Interview for ICD-10 (CIDI). Superior to the MINI,
SCID-III-R and CIDI, the MINI-Plus has speciﬁc items
for the diagnosis of drug-induced mental disorders,
e.g. drug-induced psychotic disorder.
The prevalence rates of lifetime and current per-
secutory delusion, thought reading, thought insertion,
delusion of reference, strange or unusual beliefs,
auditory hallucinations, and visual hallucinations
were rated by the patients’ responses (‘yes’ or ‘no’) to
the MINI-Plus questions. Although the MINI-Plus
separates bizarre and non-bizarre delusions, both
were combined as were the presence of delusions.
Disorganized speech, disorganized or catatonic behav-
iour, and negative symptoms were assessed on the
basis of the patient’s behaviour observed during the
interview.
The Manchester scale was used to rate the severity
of these symptoms during the week prior to assess-
ment (Krawiecka et al., 1977). This scale was chosen
because it is brief but covers a number of positive,
disorganized, and negative symptoms found in most
psychotic disorders.
The prevalence rate of each psychotic symptomwas
determined by its frequency obtained by the use of
MINI-Plus, Module M. The Manchester scale scores
were included in the factor analysis. All eight items of
the scale were subjected to principal-component
analysis for identifying the distinct factors. Eigenvalue
one test was applied to keep or discard factors. Finally,
varimax rotation was performed to elicit the factor
components.
Results
A total of 181 patients participated in the study. The
Manchester scale was not applied in 13 patients.
Therefore, the data of 168 patients (127 male and
41 female) were included in subsequent analyses.
The data of 32, 24, 50 and 50 patients were obtained
from the participating sites in Australia, Japan,
the Philippines and Thailand respectively. Most
main characteristics of the patients included in pres-
ent study are not signiﬁcantly diﬀerent across
the countries (see Table 1). By the use of Tukey
HSD post-hoc comparisons after one-way ANOVA,
Japanese participants were found to be older than
those participating in the other three countries
(F=6.67, d.f.=3, p<0.001).
During the 3 months preceding admission, 103, 55,
27 and 18 patients smoked, injected, swallowed, and
sniﬀed MA, respectively (some had more than one
route of administration). During the week prior to
admission, 26, 2, 2 and 1 patients also used marijuana,
ecstasy, inhalant, and morphine respectively. Of the
26 patients who used marijuana, 6 patients also con-
currently used cocaine, benzodiazepines, ecstasy, or
heroin. Most patients were treated with conventional
or atypical antipsychotic medications.
Table 2 shows the prevalence rates of lifetime
and current psychotic symptoms elicited by the use
of MINI-Plus, Module M. In lifetime, persecutory
delusion was the most common symptom found in
130 participants (77.4%). Other common symptoms
in lifetime were auditory hallucinations, strange or
unusual beliefs, and thought reading. Auditory hal-
lucinations were the most common current symptom
found in 75 participants (44.6%). Current symptoms
frequently found were strange or unusual beliefs and
visual hallucinations. Current negative symptoms
were also found in 36 patients (21.4%).
Delusions and hallucinations were the two most
severe symptoms during the week prior to assessment














No. of males (%) 127 (75.6) 25 (78.1) 22 (61.1) 39 (78.0) 41 (82.0) x2=5.47, d.f.=3,
p=0.14
Mean age (S.D.) 27.11 (7.62) 26.34 (6.02) 31.86 (9.79) 25.96 (5.60) 25.34 (7.33) F=6.67, d.f.=3,
p<0.001a
Mean age at ﬁrst
methamphetamine use (S.D.)
19.73 (5.93) 18.03 (5.43) 19.75 (5.26) 20.74 (5.99) 19.78 (6.55) F=1.37, d.f.=3,
p=0.26
Mean age when ﬁrst having
psychotic symptoms (S.D.)
24.95 (9.10) 25.47 (15.14) 26.15 (7.94) 24.64 (5.93) 24.10 (7.39) F=0.39, d.f.=3,
p=0.76
a Japanese participants were signiﬁcantly older than participants in the other three countries (p<0.05 by Tukey HSD post-hoc
comparisons after one-way ANOVA).
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(see Table 3). With principal-component analysis
of the Manchester scale individual items produced
three factors with an eigenvalue greater than 1. Vari-
max rotation of the principal-component analysis
yielded a three-factor model of the Manchester scale,
accounting for 69.40% of the variance. The ﬁrst factor,
which accounted for 26.64% of the variance, com-
prised poverty of speech, psychomotor retardation,
and ﬂattened/incongruous aﬀects. Because the ﬁrst
syndrome is comparable to schizophrenic negative
syndrome, it should be called ‘negative factor or syn-
drome’. The second factor, which accounted for
23.95% of the variance, consisted of delusions, hal-
lucinations, and incoherent speech. Because this
second syndrome is similar to both positive and
disorganized factors of schizophrenic psychotic
symptoms, it should be called ‘positive/disorganized
factor or syndrome’. Anxiety and depression con-
stituted an independent factor, which accounted for
18.81% of the variance.
Discussion
Although negative symptoms were not as severe as
positive symptoms, they could be found in at least
20% of the patients. The high prevalence of negative
symptoms in this study may be explained by two
reasons. First, by the use of a structured clinical inter-
view, the interviewers were obligated to observe
negative symptoms. Secondly, wide recognition of
positive and negative symptoms over the past few
decades may increase the interviewers’ awareness of
both positive and negative symptoms in this study.
The prevalence of current positive symptoms in this
study is relatively lower than that in previous studies.
While only 44.6 and 22.8% of the patients in this study
currently had auditory hallucinations and persecutory
delusions respectively, at least 75% of MA psychotic
patients in a previous study had the same symptoms
(Sato, 1992). Although the diﬀerent methods of symp-
toms assessment may be a cause of the discrepancies,
the exclusion of patients with moderate to severe
violent behaviour from this study may lead to the low
prevalence of positive symptoms. In addition, as
positive psychotic symptoms can be resolved rapidly
after a few days of MA cessation and/or antipsychotic
treatment, the opportunity to assess the patients after
many days of admission (up to 7 d in this study)
may lead to the ﬁnding of low prevalence of posi-
tive symptoms. This possibility is also supported by
the ﬁndings that, in this study, the lifetime preva-
lence of these symptoms was much higher than the
current one.
Negative and positive/disorganized syndromes
form a two-factor dimensional model of MA psychotic
symptoms. The negative syndrome comprised poverty
of speech, psychomotor retardation, and ﬂattened/
incongruous aﬀects. The positive/disorganized syn-
drome consists of delusions, hallucinations, and inco-
herent speech. Although anxiety and depression
formed another factor, they are not psychotic symp-
toms. In addition, the ﬁndings show that they can be
separated from the ﬁrst two psychotic factors.
Although the factor structures of MA and schizo-
phrenic psychotic symptoms have some similarities,
they are not identical. Two previous studies using the
Manchester scale have found a three-factor model of
schizophrenic psychotic symptoms (Johnstone and
Frith, 1996 ; Tabares et al., 2000). By separating the item
of ﬂattened/incongruous aﬀects into two, Johnstone
and Frith (1996) found a disorganized factor compris-
ing incoherent speech and an incongruous aﬀect.
The negative factor in that study consisted of poverty
of speech, psychomotor retardation, and a ﬂattened
aﬀect. Tabares et al. (2000) found a negative factor
consisting of poverty of speech and psychomotor
retardation. Flattened/incongruous aﬀects and inco-
herent speech formed a disorganized factor. Although
it is not clear why the present study ﬁnds only two
factors, the item of ﬂattened/incongruous aﬀects may
play a role. Among all items of the Manchester scale,
this is the item with the lowest inter-rater reliability
(Krawiecka et al., 1977). This may be caused by the fact
that this item inappropriately combines two diﬀerent
Table 2. Prevalence of lifetime and current psychotic
symptoms elicited by the use of MINI, Module M (n=168)
No. of patients having
symptoms (%)
Psychotic symptom Lifetime Current
Persecutory delusion 130 (77.4) 35 (20.8)
Auditory hallucinations 122 (72.6) 75 (44.6)
Strange or unusual beliefs 98 (58.3) 39 (23.2)
Thought reading 89 (53.0) 27 (16.1)
Visual hallucinations 64 (38.1) 38 (22.6)
Delusion of reference 64 (38.1) 20 (11.9)
Thought insertion or made act 56 (33.3) 18 (10.7)
Negative psychotic symptomsa 36 (21.4)
Disorganized speecha 19 (11.3)
Disorganized or catatonic behavioura 14 (8.3)
a Assessed on the basis of patient’s behaviour observed
during the interview only.
350 M. Srisurapanont et al.
symptoms, which leads to various degrees of concern
of the symptoms. The loading of this item therefore
varies from study to study. Other than being a
measuring problem, it is possible that the smaller
number of factors found in this study reﬂects the less
clinical heterogeneity of MA psychosis.
A number of clinical studies have shown that am-
phetamine and phencyclidine can induce a psychosis
that resembles schizophrenia. Although amphetamine
has long been used as a model of schizophrenia,
phencyclidine has been given an increasing amount of
attention recently. This shifting may be caused by
the fact that phencyclidine can produce a psychotic
reaction in humans that closely resembles an acute
episode of schizophrenia (Steinpresis, 1996). In ad-
dition, phencyclidine but not amphetamine can induce
social withdrawal, which is a negative symptom of
schizophrenia (Sams-Dodd, 1998). According to these
ﬁndings, amphetamine-induced psychosis may not
be an appropriate model of schizophrenia. However,
the clinical ﬁndings of this study do not support the
shortcomings of amphetamine-induced psychosis in
modelling the negative symptoms of schizophrenia.
There are some limitations of this study. First, the
eight items of the Manchester scale used in the present
study do not cover some psychotic symptoms (e.g.
disorganized behaviour and loss of drive), which
might lead to the ﬁndings of a small factor number.
Secondly, as mentioned above, the incorporation of
ﬂattened/incongruous aﬀects into a single item might
distort the factor structure. Thirdly, the negative
symptoms found in this study may be indistinguish-
able from drug-induced movement disorders because
most patients were treated with antipsychotic medi-
cations during the assessment. In addition, because
all patients had to stop using amphetamine after ad-
mission, the eﬀect of amphetamine withdrawal may
also mimic negative symptoms. Fourthly, to increase
the accuracy of diagnosis, this study excluded MA
psychotic patients who had stopped using MA for
more than 1 wk. Hence, the factor analysis described
in this study may only represent one form of ex-
pression of MA psychosis. Last, as a cross-cultural
study, the translation of the MINI-Plus, Module M and
theManchester scale may decrease their reliability and
validity. However, a beneﬁt of this sort of study is the
wider perspective of symptoms study. To our knowl-
edge, this is the ﬁrst study of its kind in which Asian
and Caucasian patients with MA psychosis took part
in the same study.
In conclusion, similar to schizophrenia and other
functional psychoses, the ﬁndings of moderately high
prevalence of negative symptoms and the existence
of negative syndrome in MA psychosis suggest that
both positive/disorganized and negative syndromes
should be taken into account in assessing MA
psychotic symptoms. Whether both syndromes have
diﬀerent underlying pathological processes and treat-
ment responses remains to be seen. The clinical ﬁnd-
ings of this study do not support the shortcomings of
amphetamine-induced psychosis in modelling the
negative symptoms of schizophrenia.
Table 3.Mean (S.D.) and factor analysis of 8-item Manchester scalea
Item Mean (S.D.) Factor 1 Factor 2 Factor 3
Negative factor
Poverty of speech or mute 0.71 (0.92) 0.86 0.07 0.02
Psychomotor retardation 0.78 (0.83) 0.83 0.04 0.25
Flattened/incongruous aﬀect 1.16 (1.01) 0.75 0.28 0.03
Positive/disorganized factor
Coherently expressed delusions 2.14 (1.24) 0.08 0.82 0.13
Hallucinations 2.02 (1.35) 0.07 0.79 0.17
Incoherent and irrelevant speech 1.11 (1.10) 0.32 0.67 x0.29
General psychopathology factor
Depression 1.14 (1.04) 0.19 x0.11 0.85
Anxiety 1.68 (1.01) 0.05 0.27 0.76
Eigenvalue 2.13 1.92 1.51
Per cent varianceb 26.64 23.95 18.81
aHighest factor loading for each rating is in bold.
b Total=69.40.
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